'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.

'Smart' insulin-delivery technologies and intrinsic glucose-responsive insulin analogues.
复制标题

DOI:
10.1007/s00125-021-05422-6
复制
发表时间:
2021-05
期刊:
影响因子:
8.2
通讯作者:
Weiss MA
Weiss MA
中科院分区:
医学1区
文献类型:
--
作者:
Jarosinski MA;Dhayalan B;Rege N;Chatterjee D;Weiss MA

文献摘要

参考文献

被引文献

相似文献

糖尿病的胰岛素替代治疗旨在最大限度地减少血糖浓度高于或低于治疗范围(高血糖或低血糖)的波动。为了减轻这种偏移的急性和慢性风险,长期以来一直在寻求葡萄糖响应性胰岛素递送技术在1型和长期存在的2型糖尿病中的临床应用。这种“智能”系统或胰岛素类似物寻求在没有外部监测的情况下提供与血糖水平成比例的激素活性。本综述强调了三种广泛的策略,以共同优化平均血糖控制和范围内的时间:(1)耦合的连续葡萄糖监测(CGM)输送设备(基于算法的“闭环”系统);(2)葡萄糖响应聚合物封装的胰岛素;(3)基于机制的激素修饰。创新涵盖了基于CGM的胰岛素递送系统的控制算法、葡萄糖响应性聚合物基质、基于胰岛素受体接合后胰岛素构象转换机制的生物启发设计以及新胰岛素类似物的葡萄糖响应性修饰。在每种情况下,胰岛素化学和配方的创新可能会提高临床结果。展望内在葡萄糖响应性胰岛素类似物含有可逆开关(调节生物利用度或构象),可以激活葡萄糖在高浓度下进行了讨论。
Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper- or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulin-delivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such ‘smart’ systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimise mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based ‘closed-loop’ systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin’s conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.
DOI: 10.1080/17425247.2017.1267138
发表时间: 2017-09
影响因子: 6.6
作者:
Bally L;Thabit H;Hovorka R
通讯作者: Hovorka R
DOI: 10.2337/diab.46.2.271
发表时间: 1997-02-01
期刊: DIABETES
影响因子: 7.7
作者:
通讯作者: --
DOI: 10.1073/pnas.1424684112
发表时间: 2015-02-24
影响因子: 11.1
作者:
Chou, Danny Hung-Chieh;Webber, Matthew J.;Anderson, Daniel G.
通讯作者: Anderson, Daniel G.
DOI: 10.1002/eji.1830090803
发表时间: 1979-01-01
影响因子: 5.4
作者:
COUTINHO, A;LARSSON, EL;ANDERSSON, J
通讯作者: ANDERSSON, J
DOI: 10.1055/s-2005-865806
发表时间: 2005-09-01
影响因子: 1.8
作者:
Becker, RHA;Frick, AD;Scholtz, H
通讯作者: Scholtz, H